> For the complete documentation index, see [llms.txt](https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/safety-interactions-and-wfa-dosing.md). # Safety, Interactions and WFA Dosing WFA does not have a validated oncology dose standard. It does have a usable safety signal. That distinction matters. This is not a no-data setting. It is an early-clinical setting that needs active monitoring and honest dose framing. ### Known human safety profile #### At extract level Standardised Ashwagandha root extracts used at `300–600 mg/day` have a well-established safety profile in human trials outside oncology. Across multiple studies, they are generally well tolerated, with no serious adverse events. Mild, transient effects include somnolence, giddiness, vertigo, drowsiness, and gastrointestinal symptoms such as nausea and loose stools. These trials mostly used root-dominant extracts designed for stress, anxiety, and sleep. WFA exposure was relatively low and was not the main driver. **IMPORTANT:** Please do not assume that any “ashwagandha” supplement will provide oncology‑relevant WFA exposure. This page was created to highlight Withaferin A‑focused targets, and specialised WFA‑standardised leaf extracts are required, not general ashwagandha root products. For support in sourcing see the **Sourcing Quality** page within this WFA in Oncology Hub. #### At WFA-specific Phase I level In the Phase I trial of oral WFA for advanced high-grade osteosarcoma, the main adverse events were liver enzyme elevation and skin rash. Other reported effects included fatigue, fever, oedema, and diarrhoea. These events occurred at doses *above* typical supplement exposure. They were generally reversible after dose reduction or discontinuation. The practical message is clear. Liver monitoring is non-negotiable at pharmacologic WFA doses. ### Preclinical safety ceiling In preclinical toxicology, oral WFA showed no deaths at single doses up to `2,000 mg/kg` in animals. It also showed a no observed adverse effect level of at least `500 mg/kg` in `28`-day repeated-dose studies. Below that ceiling, studies did not show major changes in liver or kidney function, haematology, or organ histopathology. That suggests a wide safety margin in animals, but translation to humans at oncology doses still needs caution. ### Liver safety — the main real-world caution In 2024, the Australian TGA issued a safety advisory on liver problems linked to products containing *Withania somnifera*. Twelve cases were reported. Seven had enough information to implicate the plant as a likely or possible cause. Four required hospitalisation. That signal needs context: * most reports involved whole-plant or mixed-part Ashwagandha products, not purified WFA * several cases involved multi-ingredient formulations * root-only products may have a better liver safety profile than leaf-containing products That said, oncology use should treat liver risk as clinically relevant until proven otherwise. #### Practical response * obtain baseline liver tests before starting WFA — `AST`, `ALT`, `ALP`, `GGT`, and bilirubin * recheck after introduction and after dose escalation * stop WFA and assess promptly if jaundice, dark urine, unusual fatigue, or right upper quadrant pain develops ### Thyroid effects Ashwagandha extracts and, by extension, WFA may influence thyroid hormones. Some human and case reports describe increases in `T3` and `T4`. Risk reviews also describe Ashwagandha-associated thyrotoxicosis in a small number of people. This matters most in patients with pre-existing hyperthyroidism, autoimmune thyroid disease, or thyroid medication use. Baseline and interval thyroid testing is reasonable when high-potency WFA-focused products are used for prolonged periods. ### Drug interactions — what to actually watch Most formal interaction data come from whole-extract studies. They suggest that major CYP inhibition is unlikely at typical doses. In oncology, the bigger issue is overlapping toxicity and pharmacodynamic conflict. | Drug / class | Main concern | Evidence type | Practical action | | -------------------------------------------------------------- | ---------------------------------------------------------------------------- | -------------------------------- | --------------------------------------------------------------- | | CDK4/6 inhibitors (`palbociclib`, `ribociclib`, `abemaciclib`) | Possible additive hepatotoxicity and overlapping myelosuppression monitoring | Clinical monitoring rationale | Tighten `CBC` and liver monitoring in the first overlap cycle | | Ribociclib specifically | QTc prolongation is a known ribociclib risk | Class data | Maintain standard ECG and QTc monitoring | | Antidiabetics including insulin and metformin | Additive glucose lowering and possible `AMPK/mTOR/TFEB` overlap | Pharmacologic plausibility | Monitor glucose and consider timing separation | | Antihypertensives | Possible additive blood-pressure lowering | Pharmacologic plausibility | Monitor blood pressure and symptoms | | CNS sedatives | Possible additive sedation or dizziness | Pharmacologic plausibility | Start low and go slow in frail patients | | Immunosuppressants | WFA's immune activity may oppose intended immunosuppression | Mechanistic concern | Use extra caution in transplant and fragile autoimmune settings | | Narrow-therapeutic-index CYP3A4 substrates | Major CYP3A4 interactions are unlikely, but not excluded | In vitro plus whole-extract data | Monitor clinically when exposure precision matters | ### Endocrine cautions — what has changed The older concern that Ashwagandha might raise testosterone and therefore worsen `ER+` breast cancer rests on weak evidence. It comes mainly from a small study in overweight men, not in women or cancer patients. WFA itself acts differently. It directly suppresses `ER-α` expression and signalling in `ER+` breast-cancer cells and has not been shown to raise oestrogen. Modern data also suggest that androgen receptor activation can be tumour-suppressive in `ER+` breast cancer. That weakens the old logic that more androgen necessarily means more risk. The practical message is straightforward: * treat WFA as adjunctive endocrine modulation, not a replacement for endocrine therapy * there is no evidence that pausing intermittent WFA causes `ER-α` rebound above baseline * standard decisions on aromatase inhibitors, `SERD`s, or ovarian suppression should remain guideline-led For more detail, see [Hormones — ER-α and Androgens](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/hormones-er-a-and-androgens.md). ### Pregnancy and fertility Ashwagandha has been associated with possible abortifacient effects in animal studies and case reports. Regulatory reviews have also raised reproductive safety concerns. High-potency WFA or Ashwagandha products should be avoided in pregnancy. They should also be used with great caution in people actively trying to conceive. ### Autoimmune conditions WFA and Ashwagandha can modulate immune activity. There is no strong clinical signal of common autoimmune flares, but caution is still reasonable in active autoimmune disease and in patients on strong systemic immunosuppressants. This is mainly a mechanism-based caution. It is not a well-established common adverse outcome. ### Current status of WFA dosing — what we can and cannot say #### What we do have * robust preclinical toxicology suggesting a wide safety margin in animals * a Phase I oncology trial showing that oral WFA can be given to humans with manageable toxicity * human pharmacokinetic data showing a short half-life and supporting pulse-style dosing logic #### What we do not have * a validated standard oncology dose for liposomal WFA in any cancer type * long-term human safety data at high-potency WFA doses in cancer populations * Phase II or III trial data defining dose-response relationships for efficacy ### Practical use frame The cleanest summary is this: * low-WFA, root-dominant extracts have a good general safety record * high-potency, leaf-derived, bioavailability-enhanced WFA is pharmacologically active and still experimental * the safest real-world approach uses conservative starting doses, cautious titration, and structured monitoring That means tracking liver function, blood counts, thyroid function, and relevant symptoms. It also means reducing the dose early or stopping if labs or the clinical picture start to deteriorate. ### References (Standardised Ashwagandha root extract safety at `300–600 mg/day` and higher.)\ Source: Thakare V. et al., “Safety and Tolerability of Ashwagandha (*Withania somnifera*) Root Extract in Healthy Adults: A Prospective, Non-comparative Study,” *Frontiers in Nutrition*.\ Full text: (Additional clinical data: `600 mg/day` root extract for up to `12` months, with no major safety signal.)\ Source: Verma S. et al., “Safety of 12-Months Administration of Ashwagandha (*Withania somnifera*) Root Extract,” *Phytotherapy Research*.\ Abstract: (Overview of multiple clinical trials using `300–600 mg/day` Ashwagandha root extract, with mainly mild transient adverse effects.)\ Source: National Medicines Institute, “Ashwagandha: A Review of Clinical Use and Efficacy.”\ Summary: (Clinical safety and tolerability of standardised root extract, with stable liver, kidney, and thyroid labs.)\ Source: Chandrasekhar K. et al., “Clinical Safety and Tolerability Evaluation of *Withania somnifera* Root Extract in Healthy Participants,” *Journal of Dietary Supplements*, summarised in the open-access PK and safety paper.\ Open-access summary: (Preclinical WFA toxicology, `NOAEL`, repeated-dose studies, and lack of major organ toxicity below defined doses.)\ Source: Dandekar D. S. et al., “Safety, Toxicity and Pharmacokinetic Assessment of Oral Withaferin-A.”\ Full text: (Phase I osteosarcoma WFA trial, including liver enzyme elevation and skin rash as the main reversible adverse events.)\ Source: Bolleddula J. et al., “Safety and Pharmacokinetics of Withaferin-A in Advanced Stage High-Grade Osteosarcoma,” *Journal of Ayurveda and Integrative Medicine*.\ Publisher page: (TGA advisory on Ashwagandha-related liver injury.)\ Source: Therapeutic Goods Administration, “Medicines Containing *Withania somnifera* (Withania, Ashwagandha) — Risk of Liver Injury.”\ Full advisory: (Comprehensive risk assessment covering root vs non-root parts, liver signals, thyroid signals, and overall safety profile.)\ Source: van den Berg S. J. P. L. et al., “Risk Assessment of Herbal Preparations Containing *Withania somnifera*,” RIVM Report 2024-0029.\ PDF: (Thyroid effects and Ashwagandha-associated thyrotoxicosis context.)\ Source: Mammen J. S. et al., “Ashwagandha-Induced Thyrotoxicosis: A Case Report and Literature Review,” and related safety review data.\ DOI summary: (Herb-drug interactions, CYP3A4 and CYP2D6 considerations, and the wider interaction-risk assessment for *Withania*.)\ Source: Teschke R. et al., “Comprehensive Safety Evaluation of *Withania somnifera*,” *Frontiers in Nutrition*.\ Full text: (Immune modulation and autoimmune-context relevance.)\ Source: Singh N. et al., “*Withania somnifera* (Ashwagandha) and Withaferin A: Potential in Immune Modulation and Cancer,” *Frontiers in Pharmacology*.\ Full text: (Endocrine and `ER-α` considerations.)\ Source: Sehdev V. et al., “Withaferin A Suppresses Estrogen Receptor-α Expression in Human Breast Cancer Cells,” *Molecular Carcinogenesis*.\ Full text: (Androgen receptor as a tumour suppressor in `ER+` breast cancer.)\ Source: Hickey T. E. et al., “The Androgen Receptor Is a Tumor Suppressor in Estrogen Receptor-Positive Breast Cancer,” *Nature Medicine*.\ PubMed: (Clinical breast-cancer context and endocrine cautions.)\ Source: Maharjan S. et al., “Keeping Abreast About Ashwagandha in Breast Cancer,” *Current Problems in Cancer*.\ PubMed: (Pregnancy and reproductive safety concerns.)\ Source: German Federal Institute for Risk Assessment, “Ashwagandha: Food Supplements with Potential Health Risks.”\ PDF: (Human pharmacokinetics of *Withania* extracts, half-life estimates, and inter-extract variability.)\ Source: Kandhare A. et al., “Pharmacokinetics and Bioequivalence of *Withania somnifera* Extracts in Healthy Volunteers,” *Heliyon*.\ Abstract: (Liposomal WFA bioavailability and pharmacokinetic improvement.)\ Source: Yadav K. S. et al., “Improving Oral Bioavailability and Pharmacokinetics of Liposomal Withaferin A,” *International Journal of Pharmaceutics*.\ Full text: Access and availability:\ Source: MCS Formulas, “Withaferin A Pro Liposomal.”\ `50 mg` WFA per capsule. Available via healthcare professional request.\ ### In this section #### Core pages * [Withaferin A (WFA) in Oncology](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology.md) * [Evidence Summary](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/evidence-summary.md) * [Anticancer Mechanisms](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/anti-cancer-mechanisms.md) * [Immune Effects](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/immune-effects.md) * [Synergistic Combinations](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/synergistic-combinations.md) #### Cancer-type pages * [WFA Evidence by Cancer Type](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/wfa-evidence-by-cancer-type.md) * [Breast Cancer](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/wfa-evidence-by-cancer-type/breast-cancer.md) * [Ovarian Cancer](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/wfa-evidence-by-cancer-type/ovarian-cancer.md) * [Non-Small Cell Lung Cancer](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/wfa-evidence-by-cancer-type/non-small-cell-lung-cancer.md) * [Glioblastoma](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/wfa-evidence-by-cancer-type/glioblastoma.md) * [Other Cancer Types](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/wfa-evidence-by-cancer-type/other-cancer-types.md) #### Practical pages * [Pharmacokinetics & Metabolism](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/pharmacokinetics-and-metabolism.md) * [Sourcing Quality](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/sourcing-quality.md) * [Safety, Interactions and WFA Dosing](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/safety-interactions-and-wfa-dosing.md) * [Hormones — ER-α and Androgens](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/hormones-er-a-and-androgens.md) * [Terrain Support — Liposomal WFA vs Whole-Plant Ashwagandha](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/terrain-support-liposomal-wfa-vs-whole-plant-ashwagandha.md) {% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions This documentation is published with GitBook. GitBook is the documentation platform designed so that both humans and AI agents can read, navigate, and reason over technical content effectively. Learn more at gitbook.com. ## Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter, and the optional `goal` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/safety-interactions-and-wfa-dosing.md?ask=&goal= ``` `ask` is the immediate question: it should be specific, self-contained, and written in natural language. `goal` is optional and describes the broader end goal you are ultimately trying to accomplish on behalf of the user. GitBook uses it to tailor the answer towards what is most useful for that goal. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.